Olivier Brandicourt appointed as new CEO of Bayer HealthCare

BayerOlivier Brandicourt (57) has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer AG Executive Council effective November 1, 2013. Since March 2013, Professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer AG Board Member.

"With Olivier Brandicourt we have found a strong leader with outstanding international experience and a successful track record in the healthcare industry. I am convinced that he can significantly contribute to the further growth of our healthcare business," said Bayer Group CEO Dr. Marijn Dekkers.

Brandicourt has 25 years of international experience in the pharmaceutical industry, including executive responsibilities in France, the United States, Canada and the United Kingdom. He has been a member of the Executive Leadership Team of Pfizer Inc., New York, USA, for the last three years. Until recently he was President and General Manager of the Emerging Markets and Established Products Business Units. Before that he held senior operational positions as President of the Global Specialty Business Unit, and until 2012 he was head of the Global Primary Care Business Unit. Furthermore, he previously held senior regional and country management positions at Pfizer and positions across a range of disciplines including medical and marketing at Warner-Lambert/Parke-Davis.

"I am looking forward to joining the Bayer team. With a clear focus on research and development as well as a passion and dedication to improving people’s lives, Bayer has an excellent track record in bringing innovation to the market," said Olivier Brandicourt.

Olivier Brandicourt holds a medical degree with a subspecialty in infectious diseases and tropical medicine, as well as a master’s degree in biology from Paris 12 University, France. After completing his studies, Brandicourt spent two years in the Republic of Congo as a doctor and eight years with the Institute for Infectious and Tropical Diseases at Pitié-Salpêtrière Hospital in Paris, spending half this time in West and Central Africa working on malaria research. Brandicourt is an Honorary Fellow of the Royal College of Physicians in London, UK, and a member of the Children’s Aid Society's Board of Trustees in New York. He is married with three grown-up children.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2012, the Group employed 110,000 people and had sales of €39.7 billion. Capital expenditures amounted to €1.9 billion, R&D expenses to €3.0 billion.

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...